SUVEN PHARMACEUTICALS LIMITED Company Profile Details at KooCapital.Com – Stock Market News Portal.
Suven Pharmaceuticals Limited manufactures chemical products. It specializes in providing pharmaceutical solutions to global life science companies. The firm engages in Contract Research & Manufacturing Services (CRMS) business where research and development is customized to the needs of global pharmaceutical customers. Its business segments include pharmaceutical solutions, active pharma ingredients, intermediates and formulations. The company was founded on November 6, 2018 and is headquartered in Hyderabad, Telangana.
suven pharmaceuticals limited company operating in Producer Manufacturing Sector and dealing in Industrial Conglomerates. suven pharmaceuticals limited is SEBI Listed Company (India) and having:-
ISIN (An International Securities Identification Number): INE03QK01018
Equity Stock (National Stock Exchange) Symbol: SUVENPHAR
NSE Link IS: https://www.nseindia.com/get-quotes/equity?symbol=SUVENPHAR
BSE Link IS: https://www.bseindia.com/stock-share-price/suven-pharmaceuticals-ltd/SUVENPHAR/543064/
Suven Pharma is in the business of Contract development & manufacturing organisation (CDMO), catering to the needs of global Pharma Industry.
Business Segments CDMO (Development projects and Commercial supplies) SPL engages in NCE molecule development and supply of intermediates. This is a high-value-add, high-margin business. SPL supplies intermediates for four molecules addressing rheumatoid arthritis, diabetes, depression and women’s health. This segment makes up 78% of revenues. The company has a strong order book with new clients being consistently added. Most clients are the Big Pharma companies in Europe and the US. The company is looking to shift from Intermediate to API manufacturing and is in discussion with clients regarding this. The company has stated that it has the facilities for API manufacturing.
A Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally. Suven discovery research is focused on discovering and developing new chemical entities (NCEs), which are best in class central nervous system therapies for the treatment of cognitive disorders, major depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal (Dopaminergic and serotonergic receptor), and P2X purinoceptor 7 receptor
Suven Life Sciences Ltd. stand with [In search of new CNS therapies for better living Health for patients; Value for partners]
Company Website: http://www.suven.com/
Company Website2: https://www.suvenpharm.com/
LinkedIn page URL: https://in.linkedin.com/company/suven-life-sciences-ltd.
Wiki Profile URL:
Popular Search Keywords: suven pharmaceuticals limited , company management , company history , company profile , company information , business directory , Stock Market News , annual report , quarterly results , profit and loss , Koo Capital , KooCapital.Com , KooCapital News , Producer Manufacturing Sector Company , Industrial Conglomerates industry
#suven #pharmaceuticals #limited #company #management #company #history #company #profile #company #information #business #directory #stock #market #news #annual #report #quarterly #results #profit #and #loss #koo #capital #koocapital #com #koocapital #news #producer #manufacturing #sector #company #industrial #conglomerates #industry
